Munich Re gives its views on the early stage cancer debate as part of the ABI's CI Statement of Best Practice consultation.
History shows that well established markets often come to a crossroads where changes are made. Competitive pressures inevitably drive more product options, quicker new business processes and put pressure on claims decisions, while prices get cheaper…something eventually has to give. Such pressure is building within the UK Critical Illness (CI) market and questions are being asked as to how we should proceed. This is not the first time that CI has been at such a crossroads: in 2002 a major reinsurer removed capacity from the market which contributed to changes in underwriting approa...
To continue reading this article...
Join COVER for free
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.